digital therapeutics

Novartis, Pear Therapeutics sign development deal for two digital therapeutics
By Jonah Comstock | 04:36 pm | March 01, 2018
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia.
FareWell changes name to Better Therapeutics, sees 0.8 percent A1c reduction in small study
By Jonah Comstock | 05:45 pm | February 15, 2018
San Francisco-based FareWell is changing its name to Better Therapeutics, a rebranding that reflects the company’s shift in focus from weight loss and disease prevention to digital therapeutics to treat chronic diseases.
Digital health trends and predictions for 2018, part 2
By Jonah Comstock | 05:17 pm | January 26, 2018
Last week, we published part 1 of our digital health trends and predictions piece, covering big picture trends like vertical integration and healthcare consumerization, as well as some of the buzzy tech trends of voice, AI, and blockchain.
Positive outcomes from WellDoc's BlueStar translate to cost savings, analysis finds
By Dave Muoio | 05:29 pm | January 04, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.
Pear Therapeutics rakes in $50M to develop additional digital therapeutics
By Dave Muoio | 05:11 pm | January 02, 2018
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding.